PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/190798

Please be advised that this information was generated on 2020-03-09 and may be subject to change.
The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders

Rob J. W. Arts1*, Leo A. B. Joosten1,2 and Mihai G. Netea1,3

1 Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands, 2 Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, 3 Department for Genomics and Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany

During induction of trained immunity, monocytes and macrophages undergo a functional and transcriptional reprogramming toward increased activation. Important rewiring of cellular metabolism of the myeloid cells takes place during induction of trained immunity, including a shift toward glycolysis induced through the mTOR pathway, as well as glutaminolysis and cholesterol synthesis. Subsequently, this leads to modulation of the function of epigenetic enzymes, resulting in important changes in chromatin architecture that enables increased gene transcription. However, in addition to the beneficial effects of trained immunity as a host defense mechanism, we hypothesize that trained immunity also plays a deleterious role in the induction and/or maintenance of autoimmune and autoinflammatory diseases if inappropriately activated.

Keywords: epigenetics, monocytes, immunometabolism, innate immune memory, rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis, hyper Ig-D syndrome

INTRODUCTION

Since the introduction of the term trained immunity for the non-specific memory of the innate immune system in 2011 (1), an increasing number of studies have investigated its role in homeostasis and disease. Innate immune memory has been described in plants and non-vertebrates for a relatively long time, representing the immune adaptation in these species that lack an adaptive immune system (2). In vertebrates, it was firstly shown that NK cells possess a non-specific memory that contributes in the innate host defense (3, 4). Later also monocytes and macrophages were shown to have a non-specific memory (5, 6). When human monocytes were exposed in vitro with microbial components such as β-glucan of the Candida albicans cell wall or the Bacillus Calmette-Guérin (BCG) vaccine, and a week later restimulated with non-related stimuli, the capacity of cells to produce cytokines was increased compared with non-trained (naive) cells (3, 5). Moreover, when mice were challenged (or "trained") with β-glucan or BCG in vivo, they showed lower mortality after lethal C. albicans or Staphyococcus aureus infections, a process that was largely dependent on the innate immune system (3, 5, 6). Moreover, in humans, BCG vaccination results in trained monocytes with increased responsiveness against microorganisms, which probably explains at least partly the lower mortality from a variety of infections in vaccinated children (3, 6–9).

There are a set of important characteristics that distinguish innate and adaptive immune memory processes. In case of the classical adaptive immune memory, a specific antigen is recognized and
specific T- and/or B-lymphocytes expand that specifically respond to that antigen. The breadth of needed responses is insured by gene recombination of V-D-J system. Upon reinfection, long-term memory cells will respond very specifically to the same antigen: thus, adaptive memory is both specific and enhanced, compared to the primary response. In contrast, the molecular substrate of trained immunity is epigenetically mediated, with genome-wide changes in histone marks and thus chromatin architecture playing a major role in the change of the phenotype of monocytes and macrophages (6, 10). By stimulation of an innate immune cell (or its precursors) an enhanced non-specific immunological reaction will be evoked due to differences in which gene transcription takes place due to changes in chromatin configuration (11). Innate immune memory (trained immunity) will thus evoke an increased response, but which is non-specific.

Also changes in cellular metabolism of trained macrophages were shown to be a major important component of the trained immunity phenotype. Induction of glycolysis in an mTOR/HIF-1α-dependent manner is indispensable for the induction of trained immunity (12, 13), just as induction of glutamine metabolism that results in fumarate accumulation (14, 15). Interestingly, there is a tight link between metabolic and epigenetic changes that occur in cells (16). We have for example recently shown, that induction of glycolysis is essential for the induction of epigenetic changes seen in trained immunity. When glycolysis was inhibited also the induction of trained immunity by its epigenetic changes was inhibited (12, 13). How induction of glycolysis exactly leads to epigenetic changes is still unclear, but accumulation of acetyl-CoA has been suggested as a mechanism, inducing histone acetylation (11). Moreover, also accumulation of fumarate (one of the intermediates of the TCA cycle) was shown to induce trained immunity by inhibiting histone demethylases and therefore inducing epigenetic changes in human monocytes (14). Recently, we have shown that induction of the cholesterol synthesis pathway, which results in mevalonate accumulation, is also one of the contributors to the induction of epigenetic changes in trained immunity (17). However, this remains a rather new topic of research and more research has to be performed to better understand the exact link between metabolism and epigenetics and its role in trained immunity.

Induction of trained immunity may be important for diseases characterized by defective function of innate immune responses. We have recently shown that the induction of trained immunity by β-glucan is able to counteract the epigenetic changes induced in monocytes in postsepsis immunoparalysis (18): this may represent a potential new therapy. However, trained immunity could also be the cause or play a role in maintaining disease activity in diseases characterized by excessive inflammation, although this needs to be investigated in future studies. In this review, we give an overview of literature that provides indications for the potential role of trained immunity in autoimmune and autoinflammatory diseases. We focus on the possibility that increased function of the myeloid cells in these conditions may be mediated by epigenetic rewiring, and thus possibly a trained immunity phenotype. Another possible mechanism how monocytes of patients with autoimmune and autoinflammatory diseases are more responsive is by specific genetic variations: this hypothesis has been extensively discussed in other reviews, and it will therefore be not presented here. Importantly, adaptive memory responses are also very well known to play a crucial part in autoimmune diseases. However, the role of the adaptive immune system in these diseases has been discussed elsewhere in very good recent review articles (19–21) and was therefore not included in this review.

**RHEUMATOID ARTHRITIS**

Rheumatoid arthritis (RA) is one of the most common inflammatory arthritis. The pathogenesis of this autoimmune disease is complex and remains partially elusive; it is partly genetically regulated, but environmental factors also play a role, finally leading to synovial inflammation and destruction of bone and cartilage (22). Initially, the role of the adaptive immune system was mainly studied, as the loss of self tolerance of CD4+ T lymphocytes was considered the main defect in RA (23). However, this paradigm is changing and nowadays the focus has also shifted to the role of the innate immune system in RA (24–26). Innate immune cells have been defined as being the cause of the tissue-damaging inflammatory lesions, with macrophages as main producers of proinflammatory cytokines. Macrophages are considered the cause of cartilage and bone destruction by inducing inflammation and regulating osteoclast activity, e.g., by inducing RANKL production (27–30). The number of infiltrated macrophages seems to negatively correlate with response to therapy and the degree of joint erosion (31, 32) and patients with highly active RA show a greater amount of M1-type macrophages in the synovial fluid compared to those with lower disease scores (33). Targeting the cytokines produced by macrophages [e.g., tumor necrosis factor α (TNFα)] has been proven to be a very successful treatment (34).

When circulating monocytes from RA patients were analyzed, gene expression of several proinflammatory cytokines was increased (35, 36). CD14+ monocytes showed an increased expression of CD11b, and when ex vivo stimulated, increased production of IL-1β and IL-6 is observed (37). Interestingly, PI3K/mTOR and MAPK signaling pathways are also activated in RA monocytes (36, 38), and inhibiting mTOR reduced synovial osteoclast formation and protected against local bone erosions and cartilage loss (39, 40). In addition, epigenetic changes have been suggested to play a role, although no genome wide epigenetic analyses in monocytes/macrophages have been performed. In RA synovial tissue the HAT/HDAC balance is moved into the direction of histone acetylation (41). HDAC1 and HDAC2 activity has been specifically analyzed in synovial fibroblasts (not in synovial macrophages), but no difference was found (42). Interestingly, etanercept and adalimumab downregulate trimethylation of H3K4, H3K27, H3K36, and H3K79, as well as acetylation of histone 3 and 4 at the promoter site of CCL2 (MCP-1) in monocytes which correlated with RA disease activity (43). In contrast, a recent study did not identify an increase in H3K4me3 at TNFA and Il6 genes of circulating monocytes in RA patients (44). In addition, the metabolic changes that occur in trained immunity also occur in macrophages from RA patients: upon stimulation with LPS higher levels of ATP are present in the
patient-derived macrophages (45). Glycolysis is also upregulated, as are rate-limiting enzymes (e.g., PKM2, PFKFB3, and HK2) and the glucose transporters GLUT1 and GLUT3 (46). Functionally, glucose uptake and oxygen consumption are increased (46), whereas accumulation of glutamate, succinate, and fumarate are present as signs of a highly metabolic active state of an RA proinflammatory macrophage (47, 48), similar to a trained immunity phenotype (12, 14).

Hence, multiple similarities exist between tissue macrophages or circulating monocytes in RA and trained monocytes or macrophages. Interestingly, in RA patients an increased risk for atherosclerotic disease is seen (49), which corresponds with the hypothesis that trained macrophages contribute to the development of atherosclerotic lesions (50). How the training in RA is induced remains unknown, although several danger-associated molecular patterns (DAMPs), that could be released by local sterile inflammation and tissue damage in the joint have been proposed to induce trained immunity (51), just as the increased production of IL-32 (52). Future studies to investigate these mechanisms are warranted.

**SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)**

In SLE several immunological abnormalities are present. The production of a number of antinuclear antibodies is the most prominent and well-known process, and they are used for diagnostic purposes. However, monocytes and macrophages also play a prominent role in the disease activity, which increasingly becomes a topic of research (53–55). In SLE patients, macrophages are characterized by a proinflammatory status and show an increased production of proinflammatory cytokines, such as IFNα, TNFα, and IL-6 (56–58). CD16+ monocytes express more CD80, CD86, HLA-DR, and CX3CR1 (59) and also expression data of CD14+ and non-classical monocytes demonstrate a proinflammatory phenotype (60–64). Inflammasome and interferon-regulated genes that were regulated by IRF1 (65), with IFNα as one of the main mediators (66–70), are induced in SLE monocytes. Moreover, monocytes show an improved antigen presentation capacity and are easily activated (71). It is therefore suggested that monocytes and macrophages are better capable of presenting self-antigens to autoreactive T cells and therefore inducing or maintaining disease activity (56). Interestingly, a SNP in the *IL1B* gene that was associated with lower IL-1β production upon LPS stimulation was protective for SLE (72).

Epigenetic modulation in monocytes clearly plays a role in SLE. Histones around the *TNFA* genomic region are highly acetylated in SLE monocytes resembling high accessibility for transcription (73). Also whole-genome assessment of histone H4 of monocytes reveals hyperacetylation (74–76) and also at enhancers of monocytes SLE-specific alterations for H3K4me3 and H3K27me3 could be determined (77). Whole-genome epigenetic analysis of H3K4me3 of primary monocytes of SLE patients reveals a strong association with inflammation and immune responses related genes (78, 79). When H3K4me3 modulations were related to gene promoter site, and these were compared with the major epigenetically modulated promoter sites in *in vitro* β-glucan-trained monocytes (10), the M2 and M3 clusters (defined in β-glucan training) were also significantly modulated in SLE monocytes (Table 1). In another article in which monocytes from six SLE patients were compared with six controls, 136,573 DNase hypersensitivity sites (DHS) were defined. Of these DHS, 4,583 showed SLE-specific changes for H3K4me3 and 1,714 for H3K27me3 at promoter sites. At enhancer site theses numbers were 12,109 and 3,046, respectively (55). Transcription factor binding motifs analysis revealed PU.1 and CEBPB as main transcription factors related to the H3K4me3 induced genomic areas, just as seen for β-glucan-induced training (10). Also BLIMP1 and interferon-related transcription factors as STAT1/6, and IRF1/4/8 were defined (55).

In trained immunity induced by β-glucan and also by BCG, it has been shown that important changes in cellular metabolism are induced, and that changing concentrations of metabolites play a role in the modulation of epigenetic rewiring (10, 12–14).

In immune cells from SLE patients, metabolic changes are present and might influence the epigenetic landscape as well (80). SAMs are cofactors in DNA and histone methyltransferase reactions and in T cells in SLE SAMs have been shown to be modulated and influence the epigenetic landscape, both at DNA (81, 82) and histone methylation level (83, 84). Histone demethylases need α-ketoglutrate and Fe^{2+} as cofactors, which were shown to be modulated in T cells of SLE patients (84). Acetyl CoA functions as an acetyl donor for histone acetyl transferases. Histone acetylation is defective in SLE, and when in mice in an SLE model HDACs were inhibited, this showed a positive effect on disease activity and nephritis (85–87).

Finally, also activation of the mTOR pathway is a marker of disease and of onset of disease in SLE. The mTOR pathway is activated in many immune cells, among others also in monocytes (88–90). Inhibition of mTOR with rapamycin has shown beneficial effects on several outcome measures, but monocytes/

### TABLE 1 | Comparison of H3K4me3-related GO-terms in β-trained monocytes and monocytes of SLE patients.

| Go-term | β-Glucan-induced trained immunity | SLE |
|---------|----------------------------------|-----|
| p-Value | p-Value                          |
| M1      | Sugar binding                    | 3.9E-2 | 0.72 |
| M2      | Carboxylic acid metabolic process| 7.9E-5 | 4.5E-2 |
|         | Cellular ketone metabolic process| 1.3E-4 | 0.32 |
| M3      | Lipid metabolic process          | 5.4E-6 | 3.2E-3 |
|         | Signal transducer activity       | 2.4E-3 | 3.7E-2 |
| M4      | Cofactor binding                 | 3.5E-3 | 0.16 |
| M5      | Immune response                  | 3.00E-19 | 3.7E-2 |
|         | Response to wounding             | 5.00E-17 | 1.9E-2 |
|         | Chemotaxis                       | 5.2E-7 | 0.79 |
|         | Cytokine activity                | 8.00E-12 | 5.3E-2 |
|         | Chemokine activity               | 3.7E-9 | 9.3E-2 |

H3K4me3 modulations were related to gene promoter site. Related GO-terms of the major epigenetically modulated promoter sites in *in vitro* β-glucan-trained monocytes, defined as M clusters (10), were compared with the same GO-terms in monocytes of SLE patients (78) and adjusted p-values are shown.
macrophages were unfortunately not part of the analysis [reviewed in Ref. (88)].

The modulation of monocytes from the peripheral blood could be due to changes induced in the bone marrow. Gene expression analysis of mononuclear bone marrow cells from SLE patients reveals that ERK, JNK, and p38 MAP kinases and STAT3 are significantly upregulated (91). As anti-dsDNA antibodies can bind to TLR4 and activate the NLRP3 inflammasome, it is tempting to speculate whether they might be the factor inducing trained immunity in SLE patients (92, 93).

**SJÖGREN’S SYNDROME (SS)**

Sjögren’s syndrome is a chronic autoimmune disease characterized by salivary and lacrimal gland dysfunction (94). Also in the case of SS, clues can be found in literature to suggest that a trained immunity profile may characterize its myeloid cells. Immune cell infiltrates of the salivary glands in SS mainly contain macrophages and DCs with increased IL-12 and IL-18 expression and depletion of macrophages in the gland tissue improved disease symptoms in a mouse model (95–97). When peripheral CD14+ monocytes were stimulated with apoptotic cells, they showed an increased production of TNFα or IL-1β and a decreased production of IL-10, thus displaying a proinflammatory profile (98, 99). Also when monocyte-derived dendritic cells were stimulated with LPS a clear proinflammatory profile was seen, with among others higher levels of TNFα, MIG, IFNα, IL-6, IL-12, MPI1αβ1, MCP1 compared to healthy volunteers (100). In non-stimulated circulating monocytes, type I IFN-related genes were higher expressed compared to control monocytes, which correlated with the induction of B-cell activating factor (BAFF) (101–103). When monocytes were stimulated with IFNγ, increased IL-6 and BAFF production was seen as well (104). However, others have reported different effects, with decreased cytokine production upon PPD stimulation of PBMCs isolated from SS patients (105). Furthermore, NFκB activation is promoted by reduced IkBo expression in Sjögren monocytes (106). Increased STAT1 is seen in SS monocytes (107), similar to constitutive STAT5 activation (108).

No epigenetic assessment of monocytes from SS patients has been performed, apart from increased expression of miRNA 146a and 181a in PBMCs (109–113), and miR-34b-3p, miR-4701-5p, miR-609, miR-3162-3p, and miR-877-3p upregulation in monocytes. These miRNAs collectively suppress TGFβ signaling, as opposed to proinflammatory interleukin-12 and Toll-like receptor/NFκB pathways (114). Analysis of cellular metabolic processes and induction of mTOR activation in monocytes/macrophages in SS has not been performed, but treatment with a rapamycin nanoparticle reduced destruction of lacrimal glands in a mouse model (115).

**BEHÇET’S DISEASE (BD)**

Behçet’s disease is an inflammatory disorder that is characterized by oral and genital lesions, arthritis, and uveitis. The exact cause of BD is unknown (116). Myeloid cells play an important role in Behçet’s disease activity, as granulocyte and monocyte adsorption apheresis reduced disease symptoms in two patients (117). Furthermore, peripheral monocytes of BD patients are activated and produce more proinflammatory cytokines, which might be a first clue for the presence of a trained immunity phenotype in monocytes of BD patients (118–122). The P2X7 receptor, involved in the activation of IL-1β production, has an increased expression on monocytes in BD, which is regulated by TNFα (123), while the expression of TLR2 and TLR4 is also upregulated (124, 125). The response of CD14+ monocytes from BD patients to IFNγ showed increased production of CXCL9 and CXCL10; however, the CXCL10 production might be increased due to dysregulated posttranslational regulation (126). A whole-genome DNA methylation profiling of monocytes revealed 383 CpG sites to be differently regulated compared to healthy controls (and only 123 were found in CD4+ T cells), with cytoskeleton modulation as one of the main regulated pathways (127).

**SYSTEMIC SCLEROSIS (SSc)**

Systemic sclerosis is a complex autoimmune disease with extensive fibrosis, vascular alterations and immune activation among its principal features (128). Also in SSc the monocyte compartment appears to play an important role. CD14+ monocytes levels are increased in peripheral blood and in skin infiltrates (129, 130). An increased type I IFN signature was observed in early and definite SSc patient monocytes, which correlated with increased BAFF mRNA expression. Production of other cytokines, chemokines and their receptors (among others IL6, TNFα, and TGFβ) is upregulated as well (131–145). Monocytes of SSc patients produce more reactive oxygen species (146, 147), whereas nitric oxide production was decreased (148). SSc PBMCs produce more IL-8 and CCL18 when stimulated with IgG (149). In the vascular alterations present in SSc patients, monocytes appear to play a role as they can differentiate into fibroblast-like cells and produce extracellular matrix (modulating) proteins, resulting in a proangiogenic but impaired vasculogenic environment (132, 150–156). The macrophage activation markers CD163 and CD204 are more expressed in SSc (129, 132), which by some authors has been linked to a M2 macrophage phenotype with anti-inflammatory and profibrotic features (157). The alveolar macrophages in SSc patients with pulmonary fibrosis have a strong M2 phenotype with expression of CCL17, CCL18, and CCL22 and increased activation of STAT 3 (158). Increased TNFα production by these cells was also reported (159).

On the level of epigenetic profiles, hardly any data are available in monocytes or macrophages from SSc patients. The only data available in monocytes show that histone demethylation plays a role in the production of tissue inhibitor of metalloproteinases 1 in the presence of TLR8 stimulation (160). However, given the broad amount of data present in the literature, an epigenetic analysis on circulating monocytes in SSc would be a logical next step.

**WEGENER’S GRANULOMATOSIS (WG)**

Wegener’s granulomatosis is a systemic inflammatory disorder characterized by vasculitis of the small- and medium-size vessels
in many organs. The exact cause remains unknown, but monocytes have been suggested to play a role in disease activity (161).

Monocytes of WG patients are activated, as shown by increased CD11b and CD64 expression, and increased concentrations of neopterin and IL-6 are found in the serum (162). The expression of adhesion molecules is increased on monocytes from WG patients (163). Interestingly, anti-PR3 induces cytokine production by monocytes and it was shown that when monocytes are primed with ANCA or PR3 antibodies, their responses to LPS and LTA stimulation increase, with more TNFα, IL-6 and IL-8 production (164) and increased expression of CD14, CD18, and several PRRs (165, 166). Monocytes of WG patients that did not respond to methotrexate showed increased intracellular levels of IL-12 and TNFα (but no IL-8) that normalized after cyclophosphamide treatment (167). Also IL-8, IL-12, and MCP-1 production was increased in WG monocytes (166, 168–170). In contrast, other studies have shown that monocytes from WG patients are shown to produce less reactive oxygen species and have impaired phagocytosis (171) and in one report, monocytes of WG patients were stimulated with LPS, they produced less TNFα compared to healthy controls (172). No studies on epigenetic modulation of cellular metabolism of monocytes in WG are available. In order to assess whether a trained immunity phenotype is indeed responsible for the functional changes observed, such studies should be performed.

SARCOIDOSIS

Sarcoidosis is a complex systemic granulomatous disorder of unknown etiology. Circulating monocytes of sarcoidosis patients produce less IL-10 (173), express more CD16+ (174, 175), BAFF (166), TLR2 and TLR4 (176), IL-2R (177), adhesion molecules (178), produce more proinflammatory cytokines (176, 179–181) and oxygen radicals (182), and have increased phagocytic activity (183), thus showing an increased activated phenotype (184). Moreover, monocytes of sarcoidosis patients are more likely to form giant cells (185). Fibrin, which is newly formed in granulomas, is able to induce IL-1β production and might therefore serve as an inducer of trained immunity (186).

RNA-sequencing analysis of monocytes of sarcoidosis patients revealed several differentially expressed genes, with enrichment of ribosome, phagocytosis, lysosome, proteasome, oxidative phosphorylation, and metabolic pathways are the main pathways (187). No epigenetic analysis of monocytes in sarcoidosis has been done so far (188).

TYPE 1 DIABETES MELLITUS (T1DM)

Type 1 diabetes mellitus is an important autoimmune disease resulting in profound defects in glucose metabolism. The exact underlying mechanism is unknown, but autoimmune destruction of β-cells of the pancreas is the cause of insulin deficiency (189). Monocytes and macrophages are thought to play a key role in the development of T1DM (190, 191). When peripheral blood monocytes from recent-onset T1DM patients were assessed, more CD14+CD16+ monocytes were found, which was negatively correlated with insulin and C-peptide serum levels. Furthermore, these monocytes showed higher expression of HLA-DR and CD86, and showed an activated proinflammatory phenotype (192–196). In recent-onset T1DM patients, plasma TNFα levels were higher which correlated with CD14 expression (197). However, another study showed decreased total number of monocytes in T1DM (198). Serum levels of MIF and MCP-1 are also increased (199). Prior to development of T1DM, children show an IFN transcriptional signature in PBMCs, which might be a result of a recent upper respiratory infection. Increased expression of SIGLEC-1 on CD14+ monocytes was also found (200). Furthermore, it was shown that IL-1β plays a central role in the inflammation seen in T1DM (201) and that during the development of T1DM TLR-induced IL-1β and IL-6 production from monocytes is enhanced (202). Importantly, inhibiting IL-1β production or IL-1β signaling can improve T1DM outcome (203–206). In contrast, monocyte-derived DCs did not appear to be affected in recent-onset T1DM (191).

Epigenetics has been proposed to play a role in T1DM as well (207). Assessment of DNA methylation profiles of 32 T1DM patients versus 31 healthy individuals revealed 153 hypomethylated and 225 hypermethylated loci in whole blood, and, respectively, 155 and 247 in monocytes. However, whether these are causative to the disease or a consequence of the pathological process remains unclear (208). In another study methylation variable positions were assessed in monocytes prior to development of T1DM: 132 positions were identified and associated with a gene, with important immunology-related genes as HLA-DQB1, HLA-DRB1, NFKB1A, and TNF as major examples (209). Also important histone modifications were seen in H3K9ac in monocytes, but also these were more likely to be induced after development of the disease (210). However, in one study, H3K9ac at HLA-DRB1 and HLA-DQB1 of monocytes was shown to correlate with T1DM susceptibility prior to disease (211). Differences in H3K9me3 in inflammatory and autoimmune-related pathways were found in lymphocytes of T1DM patients, but no differences were found in monocytes (212).

Cellular metabolism of monocytes in T1DM prior to disease onset is still poorly known. Only one study revealed changes in the transcriptional signature of cell metabolism, cell survival, and oxidative stress in monocytes of recent-onset DM1. Interestingly, one of the main induced genes was HIF1α (213), although mTOR does not appear among the significantly differently regulated genes.

Lastly, as BCG is able to induce trained immunity, it could be expected that BCG-vaccinated children are at higher risk to develop T1DM. However, in an observational trial no such correlation has been found (214, 215). Interestingly, in a randomized controlled trial, BCG was suggested to have a beneficial effect on insulin production, as induction of TNF production resulted in reduced autoimmune phenotype of innate immune cells and induction of Treg (216, 217).

AUTOINFLAMMATORY DISORDERS

Autoinflammatory disorders or periodic fever syndromes consist of a set of diseases that are characterized by periodic episodes of fever and inflammation. Common symptoms
are joint pain, rash, abdominal pain, and long-term disease can result in amyloidosis. These diseases are not induced by autoantibodies or autoreactive T-cells but are the result of a hyperfunctional innate immune system, which is due to genetic defects. The familial autoinflammatory syndromes are generally rare, and the pathogenesis is not well understood for some of them (218). Here, we argue that trained immunity could be a likely contributor to these diseases.

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a multisystemic autoinflammatory condition associated with heterozygous TNFRSF1A mutations, presenting with a variety of clinical symptoms, many of which still unexplained. TRAPS monocytes shown an inflammatory baseline state, with enhanced IL1β and IL1R1 gene expression, also in non-active disease, whereas IFN and TGFβ are downregulated (219, 220). Also CD16 expression is upregulated (221) and MAPK can be spontaneously activated (220). Interestingly, a TRAPS patient with a monocytic fasciitis has been successfully treated with tacrolimus (an mTOR inhibitor) (222).

Cryopyrin-associated periodic syndromes (CAPS) are caused by a mutation in NLRP3 inflammasome, resulting in increased IL-1β and IL-18 production, but impaired production of the anti-inflammatory IL-6 and IL-1RA cytokines (223, 224). Interestingly, although the genetic defect is the main cause of these abnormalities, epigenetic analysis of CAPS monocytes revealed that DNA methylation was also affected, resulting at increased expression of inflammasome-related genes. When CAPS patients were treated with IL-1 neutralizing therapies, their methylation profile reversed toward that of healthy controls (225).

In familial Mediterranean fever (FMF), ex vivo LPS-stimulated PBMCs and monocytes produce more IL-1α and β, IL-6, IL-8, IL-12, IL-18, and TNFα, and in non-stimulated PBMCs higher production of IL-6 and TNFα was found (226–230), and also expression of CD11b was increased (231).

Hyper-IgD syndrome (HIDS) is an autoinflammatory disorder caused by a mutation in mevalonate kinase (232, 233), in which patients experience periodic attacks of sterile inflammation with symptoms such as fever, skin lesions, lymphadenopathy, and arthralgia (234). Interestingly, PBMCs of HIDS patients produce more cytokines in unstimulated as well as stimulated state and the IgD itself was able to induce cytokine production (235–238). In a whole-blood transcriptome analysis several glycolysis-related genes were higher expressed in HIDS patients, which decreased after canakinumab treatment (239). In addition, we recently have shown broad genome-wide changes in the H3K27Ac marker in monocyes of HIDS patients, which are due to mevalonate accumulation and are believed to express a trained immunity profile (Bekkering et al., 2018 Cell in press).

The common factor in these autoinflammatory syndromes is overproduction of IL-1β, which is one of the reasons why anti-IL-1 therapeutic approaches are successful (240). As IL-1β is considered as a causal factor and plausibly plays a role in maintaining disease, accumulating evidence suggests that IL-1β is an important inducer of trained immunity. Interestingly, old studies have shown that injection of IL-1β in mice prevented death from subsequent bacterial and fungal infections (241, 242). It is tempting to hypothesize that IL-1β induces trained immunity and prevent from the subsequent infections, by epigenetically modifying monocytes and macrophages resulting in more proinflammatory immune cells. To further substantiate this hypothesis, we have recently performed experiments in which human monocytes are ex vivo trained with IL-1β. This indeed resulted in trained monocytes that produced more IL-6 and TNFα upon restimulation with LPS, and also increased H3K4me3 occupancy at the promoters of IL6 and TNFAf was observed (Arts et al., Cell Host Microbe 2018, in press). While IL-1 can induce beneficial effects in infections through induction of trained immunity, a negative consequence could be induction of overinflammation, which might result in an autoinflammatory disease. This thus opens a potential new field of research, where trained immunity in these autoinflammatory diseases should be further evaluated.

**CHRONIC GRANULOMATOUS DISEASE (CGD)**

Chronic granulomatous disease is an inherited immunological disorder, in which intracellular superoxide radical production is deficient. Although CGD is an immunodeficiency, it also has autoinflammatory characteristics, which is why it is discussed here as well. Normally CGD presents in the first years of life with severe recurrent bacterial and fungal infections, but it can also present later in life (243). CGD phagocytes are impaired in destroying phagocytozed microorganisms, rendering the patients susceptible to bacterial and fungal infections. Besides this immunodeficiency, CGD patients suffer from various autoinflammatory symptoms, such as granuloma formation and Crohn-like colitis (244). Also monocytes from CGD patients display a proinflammatory phenotype with increased secretion of inflammasome-mediated cytokines (IL-1β, IL-18) possibly due the inflammasome triggering effect of ROS, but also increases of other cytokines and chemokines, and NKκB and ERK expression upon stimulation (245–247). Circulating monocytes display an inflammatory phenotype with more CD16+ expression and more intracellular IL-1β and TNFα (247). However, others have shown lower TNFα production by CGD monocytes (248). Incubation of CGD monocytes with rapamycin (an mTOR inhibitor) counterbalanced the preactivation state of monocytes ex vivo (247), hence implicating a role for mTOR. IL-1 inhibition reduced inflammation in humans and reduced disease activity of, e.g., CGD-associated colitis, possibly also by restoring autophagy (249, 250). Interestingly, injection of fungal β-glucan results in hyperinflammation and necrosis in CGD mice associated with increased IL-1β, IL-6, and TNFα production (251–253).

Metabolically also clear differences were found in CGD monocytes. Several metabolites of the tryptophan pathway accumulate and indoleamine 2,3-dioxygenase is activated (254), just as seen in monocytes stimulated with LPS or IFNγ (255). CGD monocytes have been shown to higher acidification (256), which might be the result of increased lactate production.
| Cytokines and chemokines | Metabolism of immune cells | Epigenetic marks | mTOR signaling | Others |
|--------------------------|---------------------------|-----------------|---------------|--------|
| **Rheumatoid arthritis** | Circulating monocytes have increased expression of proinflammatory cytokines (35, 36) Ex vivo-stimulated monocytes produce more IL-1β and IL-6 (37) | Higher ATP levels upon LPS stimulation of macrophages (45) Upregulated glycolysis (46) Increased oxygen consumption (46) Accumulation of succinate in macrophages (47) Accumulation of succinate, fumarate, glutamate in synovial fluid (48) | H3K4me3 at TNFA and IL6 is not induced in monocytes (44) PI3K/mTOR signaling pathway and MAPK are activated in RA monocytes (36, 38) | Increased CD11b expression on CD14 circulating monocytes (37) |

| **SLE** | Circulating monocytes produce more proinflammatory cytokines (56–58) SNP in the IL1B gene was protective for SLE (72). | No studies specific on monocytes | Histones around TNFA are highly acetylated in monocytes (73) Histone H4 of monocytes is hyperacetylated (74–76) H3K4me3 of SLE monocytes are associated with inflammation and immune response-related genes (78, 79) SLE-specific H3K4me3 and H3K27me3 (enhancer) modifications (55, 77) | Activated mTOR pathway in monocytes/macrophages (88–90) Rapamycin inhibition improves outcome (88) | CD16+ monocytes express more CD80, CD86, HLA-DR and CX3CR1 (59) CD14+ and non-classical monocytes display a proinflammatory phenotype (60–64) Inflammasome and interferon-regulated genes are induced in monocytes (65–70) Monocytes show an improved antigen presentation capacity (71) ERK, JNK, and p38 MAP kinases and STAT3 are significantly upregulated in mononuclear bone marrow cells (91). |

| **Sjögren** | CD14+ monocytes stimulated with apoptotic cells show increased TNFα and IL-1β, and decreased IL-10 production (98, 99). Monocyte-derived DCs produce more proinflammatory cytokines (100) Higher expression of IFN-I-related genes, which correlated with BAFF (101–103) IFNy-stimulated monocytes produce more IL-6 and BAFF (104) | ? | Several miRNAs are upregulated in monocytes (114) | ? | NFκB activation is promoted by reduced Ικκκ expression in monocytes (106) Increased STAT1 activation (107) Constitutive STAT5 activation (108) |

| **Behçet’s disease** | Peripheral monocytes are activated and produce more proinflammatory cytokines (119–122) Increased production of CXCL9 and 10 upon IFNy stimulation (126). | ? | DNA methylation profiling of monocytes revealed 383 CpG sites to be differently regulated in monocytes (127) | ? | Increased P2X7 receptor (123), and TLR2 and 4 expression (124, 125) |

| **Systemic** | Monocytes display an increased IFN type I signature, but also other cytokines, chemokines and their receptors are upregulated (131–145) A SNP in TLR2, which results in increased production of TNFα and IL-6 of monocytes, was associated with SSC (257) | ? | ? | ? | Monocytes produce more ROS (146, 147), whereas NO production is decreased (148) Increased expression of CD183 and CD204 (129, 132) |

(Continued)
| Cytokines and chemokines | Metabolism of immune cells | Epigenetic marks | mTOR signaling | Others |
|--------------------------|---------------------------|-----------------|---------------|--------|
| Wegener’s granulomatosis | Increased IL-6 expression (162) | ? | ? | Increased CD11b and CD64 expression (162) and CD14, CD18, and several PRRs (165, 166) Increased expression of adhesion molecules (163) |
| Sarcoidosis | Higher production of proinflammatory cytokines (176, 179-181) | RNA-sequencing of monocytes shows enrichment of oxidative phosphorylation and metabolic pathways (187) | ? | Higher expression of CD14+CD16+ (174, 175), BAFF (166), TLR2 and 4 (176), IL-2R (177), adhesion molecules (179) Higher production of oxygen radicals (182) and increased phagocytic activity (183) More likely to form giant cells (185) |
| T1DM | Higher plasma levels of TNF, MCP-1, and MIF (197, 199), and TLR-induced IL-1β and IL-6 production by monocytes is increased (200-202), IL-1β inhibition improves T1DM outcome (203-206) | Gene expression of recent-onset T1DM monocytes shows signature with cellular metabolism and oxidative stress as main pathways, and with HIF1A among the induced genes (213) | Several DNA hypo and hypermethylated loci were defined in T1DM monocytes (208, 209), H3K9ac marks are correlated with T1DM (210, 211) | More CD14 + CD16+ monocytes in recent-onset T1DM patients, with higher HLA-DR and CD86 expression and proinflammatory phenotype (192-196). |
| TRAPS | Enhanced IL1B and IL1R1, and decreased IFN and TGFβ expression (219, 220) | ? | ? | Monocytic fasciclitis successfully treated with tacrolimus (222) Upregulated CD16 expression (221) Spontaneous MAKP activation (220) |
| CAPS | Increased IL-1β and IL-18 production, Production of IL-6 and IL-1β appears to be impaired (223, 224) | DNA methylation was affected, resulting at increased expression of inflammasome-related genes (225) | ? | ? |
| FMF | LPS-stimulated PBMCs and monocytes produce more IL-1α and β and non-stimulated PBMCs produce more of IL-6 and TNFα (226-228) | ? | ? | Higher expression of CD11b (231) |
| HIDS | PBMCs produce more cytokines in unstimulated or stimulated state (235-238) | ? | ? | ? |
| CGD | Monocytes display a proinflammatory phenotype with increased secretion of IL-1β and IL-18, but also other cytokines and chemokines (245-247) More IL-1β and TNFα expression (247) | Metabolites of the tryptophan pathway accumulate and indoleamine 2,3-dioxygenase (IDO) is activated (254) Monocytes show higher acidification (256) | ? | Incubation of monocytes with rapamycin counterbalanced the preactivation state (247) Increased NK-κB and ERK expression upon stimulation (246, 247) More CD16+ expression (247) |
CONCLUSION

In this review, we present an overview of the data supporting the concept that monocytes from patients with several autoimmune and autoinflammatory diseases display features consistent with a trained immunity phenotype. The phenotype of a trained monocyte has been defined with characteristics as (1) increased cytokine production, (2) changes in cellular metabolism (mainly increased glycolysis and lactate production), and (3) epigenetic rewiring (Table 2). Trained immunity could serve a role in the initiation of the disease and in the maintenance or aggravation of the symptoms. In the case of disease initiation, a genetic or environmental factor (or combinations of both) would induce trained monocytes/macrophages that initiate the disease. In the case of disease progression, monocytes/macrophages become trained and are therefore easier activated, which would result in the maintenance or deterioration of disease symptoms. This is an important distinction to take into account, as different experimental approaches would apply.

By providing a molecular mechanism in the described diseases in terms of trained immunity, we inherently describe potential novel therapies. For certain components of the metabolic pathways and epigenetic pathways described to be important for trained immunity, specific and non-specific inhibitors are already available and new ones are being developed. We have shown before that by inhibiting specific metabolic pathways or by specifically inhibiting certain epigenetic modulating enzymes, the induction of trained immunity can be counteracted (12–15). Hence, by identifying the specific trained immunity pathways that play a role in the induction and progression of disease activity in these autoinflammatory and autoimmune diseases, it is hoped that novel targeted immunotherapies will be developed.

However, all data presented here are circumstantial and do not prove a causal relation between the disease symptoms and monocyte function. Therefore, specifically applied experiments on the role of trained immunity in these diseases are essential to further unravel the role of trained immunity. By elucidating the potential role of trained immunity in these (but supposedly also other) diseases, new steps can be made in better understanding the pathophysiology of these diseases. Even more importantly, this could potentially lead to new approaches for therapeutic intervention in these diseases.

AUTHOR CONTRIBUTIONS

RA wrote the first draft and LJ and MN made revisions.

FUNDING

MN was supported by an ERC Consolidator Grant (#310372) and a Sinoza Grant of the Netherlands Organization for Scientific Research. LJ was supported by a Competitiveness Operational Programme grant of the Romanian Ministry of European Funds (HINT, ID P_37_762; MySMIS 103587).

REFERENCES

1. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe (2011) 9(5):355–61. doi:10.1016/j.chom.2011.04.006
2. Milutinovic B, Kurtz J. Immune memory in invertebrates. Semin Immunol (2016) 28(4):328–42. doi:10.1016/j.smim.2016.05.004
3. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol (2014) 155(2):213–9. doi:10.1016/j.clim.2014.10.005
4. O’Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Science (2015) 345(6204):1251079. doi:10.1126/science.1250684
5. Quintin J, Saeed S, Martens JH, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe (2012) 12(2):223–32. doi:10.1016/j.chom.2012.06.006
6. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Iirim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from infection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A (2012) 109(43):17537–42. doi:10.1073/pnas.1202870109
7. Aaby P, Keulmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol (2014) 15(10):895–9. doi:10.1038/nl.2961
8. Aaby P, Roth A, Ravn H, Napier BM, Rodrigues A, Lisse IM, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis (2011) 204(2):245–52. doi:10.1093/infdis/jir240
9. Arts RJW, Moolgag S, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe (2018) 23(1):89–100e5. doi:10.1016/j.chom.2017.12.010
10. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajareifah A, Matese F, et al. Epigenetic programming of monocyte-to-macroage differentiation and trained innate immunity. Science (2014) 345(6204):1251086. doi:10.1126/science.1251086
11. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science (2016) 352(6284):afaf1098. doi:10.1126/science.aaf1098
12. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (2014) 345(6204):1250684. doi:10.1126/science.1250684
13. Arts RJ, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep (2016) 17(10):2562–71. doi:10.1016/j.celrep.2016.10.008
14. Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkerling S, Lachmandas E, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab (2016) 24(6):807–19. doi:10.1016/j.cmet.2016.10.008
15. Arts RJ, Joosten LA, Netea MG. Immunometabolic circuits in trained immunity. Semin Immunol (2016) 28(5):425–30. doi:10.1016/j.smim.2016.09.002
16. Donohoe DR, Bultman SJ. Metabolooepigenetics: interrelationships between energy metabolism and epigenetic control of gene expression. J Cell Physiol (2012) 227(9):3169–77. doi:10.1002/jcp.24054
17. Bekkering S, Arts RJW, Novakovic B, Kourtzielis I, van der Heijden C, Li Y, et al. Metabolic induction of trained immunity through the mevalonate metabolic and epigenetic programs in trained immunity. Science (2014) 345(6204):1250684. doi:10.1126/science.1250684
18. Catsma AI, Joshua V, Klareskog L, Malmstrom V. Mechanisms involved in Toll-like receptor 2-induced trained innate immunity. Immunity (2012) 36(4):549–61. doi:10.1016/j.immuni.2012.02.014
19. Arts RJ, Joosten LA, Netea MG. Immunometabolic circuits in trained immunity. Semin Immunol (2016) 28(5):425–30. doi:10.1016/j.smim.2016.09.002
20. Collectif VA, Tsokos GC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 125(6):2220–7. doi:10.1172/JCI80677
21. Bordignon C, Canu A, Dyczko A, Leone S, Monti P. T-cell metabolism as a target to control autoreactive T cells in beta-cell autoimmunity. *Curr Diab Rep* (2017) 17(9):1-11. doi:10.1007/s11892-017-0848-5

22. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* (2011) 365(23):2205–19. doi:10.1056/NEJMra1004965

23. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet* (2001) 358(9285):903–11. doi:10.1016/S0140-6736(01)06075-5

24. Theofilopoulos AN, Gonzalez-Quintal R, Lawson BR, Koh YT, Stern ME, Kono DH, et al. Sensors of the innate immune system: their link to rheumatic diseases. *Nat Rev Rheumatol* (2010) 6(3):146–56. doi:10.1038/nrrheum.2009.278

25. Waldner H. The role of innate immune responses in autoimmune disease development. *Autoimmun Rev* (2009) 8(5):400–4. doi:10.1016/j.autrev.2008.12.019

26. Takai T. Roles of Fc receptors in autoimmunity. *Nat Rev Immunol* (2002) 2(8):580–92. doi:10.1038/nr856

27. Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegele H, et al. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. *Arthritis Rheumatol* (2014) 66(11):2989–3000. doi:10.1002/art.38624

28. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. *J Immunol* (2001) 166(8):4915–21. doi:10.4049/jimmunol.166.8.4915

29. Horwood NJ. Macrophage polarization and bone formation: a review. *Clin Rev Allergy Immunol* (2016) 51(1):79–86. doi:10.1007/s12120-015-8519-2

30. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. *Front Immunol* (2014) 5:511. doi:10.3389/fimmu.2014.00511

31. Gerlag DM, Tak PP. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. *Best Pract Res Clin Rheumatol* (2008) 22(2):311–23. doi:10.1016/j.berh.2008.02.002

32. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. *Arthritis Rheum* (1996) 39(1):115–24. doi:10.1002/art.1780390116

33. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. *Arthritis Rheum* (2009) 60(5):1210–21. doi:10.1002/art.24505

34. Onuora S. Rheumatoid arthritis: anti-TNF agents go head-to-head. *Rheumatol* (2015) 4(6):584–96. doi:10.2119/molmed.2014.00511

35. Stuhlmüller TC, Mikkers HMM, Huizinga TW, Toes REM, van der Helm-van Mil AHM, Kurreeman F. Inflammatory genes TNFalpha and IL-6 display no signs of increased H3K4me3 in circulating monocytes from untreated rheumatoid arthritis patients. *Genes Immun* (2017).

36. Shirai T, Nazarewicz RW, Wallis BR, Yanes RE, Watanabe R, Hilhorst M, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. *J Exp Med* (2016) 213(3):337–54. doi:10.1084/jem.20150900

37. Littlewood-Evans A, Sarret S, Apfel V, Loesle P, Dawson J, Zhang J, et al. GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. *J Exp Med* (2016) 213(9):1655–62. doi:10.1084/jem.20160061

38. Kim S, Hwang J, Xuan J, Jung YH, Cha HS, Kim KH. Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis. *PLoS One* (2014) 9(6):e97501. doi:10.1371/journal.pone.0097501

39. Fransen J, Kazemi-Bajestani SM, Breide SJ, Popa CD. Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis. *PLoS One* (2016) 11(6):e0157360. doi:10.1371/journal.pone.0157360

40. Christ A, Bekkering S, Latz E, Riksen NP. Long-term activation of the innate immune system in rheasclerosis. *Semin Immunol* (2016) 28(4):384–93. doi:10.1016/j.smim.2016.04.004

41. Crisan TO, Netea MG, Joosten L.A. Innate immune memory: implications for host responses to damage-associated molecular patterns. *Eur J Immunol* (2016) 46(4):817–28. doi:10.1002/eji.201545897

42. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, et al. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. *Ann Rheum Dis* (2011) 70(4):660–7. doi:10.1136/ard.2010.139196

43. Pisetsky DS. The role of innate immunity in the induction of autoimmunity. *Autoimmun Rev* (2008) 8(1):69–72. doi:10.1016/j.autrev.2008.07.028

44. Morell M, Varela N, Maranon C. Myeloid populations in systemic autoimmune diseases. *Clin Rev Allergy Immunol* (2017) 53(2):199–218. doi:10.1007/s12016-017-8606-7

45. Liu L, Yin X, Wen L, Yang C, Sheng Y, Lin Y, et al. Several critical cell types, tissues, and pathways are implicated in genome-wide association studies for systemic lupus erythematosus. *G3 (Bethesda)* (2016) 6(6):1503–11. doi:10.1534/g3.116.027326

46. Kavai M, Szegedi G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. *Autoimmun Rev* (2007) 6(7):497–502. doi:10.1016/j.autrev.2007.01.017

47. Sestak AL, Furnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of inflammation, bone, and beyond. *Nat Rev Immunol* (2017) 17(1):12–20. doi:10.1038/nri4159

48. Steinbach F, Henke F, Krause B, Thiele B, Burmester GR, Hiepe F. Monocytes from systemic lupus erythematosus patients are severely altered in phenotype and lineage flexibility. *Ann Rheum Dis* (2000) 59(4):283–8. doi:10.1136/ard.59.4.283

49. Zhu H, Hu F, Sun X, Zhang X, Zhu L, Liu X, et al. CD16+ Monocyte subset was enriched and functionally exacerbated in driving T-cell activation and B-cell response in systemic lupus erythematosus. *Front Immunol* (2016) 7:512. doi:10.3389/fimmu.2016.00512

50. Lyons PA, McKinney EF, Rayner TF, Hatton A, Wofendin HR, Koulakoudi M, et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. *Ann Rheum Dis* (2010) 69(6):1208–13. doi:10.1136/ard.2009.108043

51. Dozmorov MG, Dominguez N, Bean K, Macwana SR, Roberts V, Glass E, et al. B-cell and monocyte contribution to systemic lupus erythematosus...
Arts et al.

identified by cell-type-specific differential expression analysis in RNA-seq data. *Bisinform Biol Insights* (2015) 9(Suppl 3):11–9. doi:10.4137/BBI.S29470

Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-Classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematosus. *Sci Rep* (2015) 5:13886. doi:10.1038/srep13886

O’Gorman WE, Hsieh EW, Gherardini PF, Hernandez JD, Hansmann L, et al. Single-cell systems-level analysis of human toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. *J Allergy Clin Immunol* (2015) 136(5):1326–36. doi:10.1016/j.jaci.2015.04.008

Shi L, Zhang Z, Wu AM, Wang W, Wei Z, Akhter E, et al. The SLR transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. *PLoS One* (2014) 9(5):e93846. doi:10.1371/journal.pone.0093846

Liu J, Berthier CC, Kahlenberg JM. Enhanced inflammasome activity in systemic lupus erythematosus is mediated via type I interferon upregulation of interferon regulatory factor 1. *Arthritis Rheumatol* (2017) 69(9):1840–9. doi:10.1002/art.40166

Lozano J, Rodriguez-Carrio J, Caminal-Montero L, Mozo L, Suarez A. A pathogenic IFNalpha, BLyS and IL-17 axis in systemic lupus erythematosus patients. *Sci Rep* (2016) 6:20651. doi:10.1038/srep20651

Eloranta ML, Ronnblom L. Cause and consequences of the activated type I interferon system in SLE. *J Mol Med (Berl)* (2016) 94(10):1103–10. doi:10.1007/s00109-016-1421-4

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci U S A* (2003) 100(5):2610–5. doi:10.1073/pnas.0337679100

Byrne JC, Ni Gabhann J, Lazzari E, Mahony R, Smith S, Stacey K, et al. Genetics of SLE: functional relevance for monocytes/macrophages in disease. *Clin Dev Immunol* (2012) 2012:582352. doi:10.1155/2012/582352

Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polyadenylation in sepsis and systemic lupus erythematosus. *Arthritis Rheumatol* (2016) 69(10):1103–10. doi:10.1002/art.40166

Zhang Z, Song L, Maurer K, Petri MA, Sullivan KE. Cytokine-induced TRIM in Diseases
phagocytosis. *Clin Exp Immunol* (2014) 177(3):662–70. doi:10.1111/cei.12378

99. Hal C, Oshholm P, Tvede N, Bendtzen K. Blood mononuclear cells in patients with primary Sjögren's syndrome: production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis. *Scand J Rheumatol Suppl* (1986) 61:131–4.

100. Volchenkov R, Brun JG, Jonsson R, Appel S. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. *Arthritis Res Ther* (2013) 15(5):R114. doi:10.1186/ar4294

101. Béki Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression. *Ann Rheum Dis* (2013) 72(5):728–35. doi:10.1136/annrheumdis-2012-201381

102. Pauley KM, Stewart CM, Gauna AE, Dupre LC, Kuklani R, Chan AL, et al. Characterization of monocyte/macrophage subsets in the skin and predominant in T cells, B cells and monocytes from patients with primary Sjögren's syndrome. *Clin Exp Immunol* (2015) 181(1):29–38. doi:10.1111/cei.12614

103. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Regulatory mechanisms for the production of BAFF and IL-6 are impaired prematurely in T cells, B cells and monocytes from patients with primary Sjogren's syndrome. *Arthritis Res Ther* (2010) 31(4):729–35.

104. Lisi S, Sisto M, Lofrumento DD, D'Amore M. Altered IkappaBalpha expression promotes NF-kappaB activation in monocytes from primary Sjögren's syndrome patients. *Patology* (2012) 44(6):557–61. doi:10.1097/PAT0b013e3283580388

105. Pertovaara M, Silvennoinen O, Isomaki P. Cytokine-induced STAT1 activation is increased in patients with primary Sjögren's syndrome. *Clin Immunol* (2016) 165:60–7. doi:10.1016/j.clinimm.2016.03.010

106. Pertovaara M, Silvennoinen O, Isomaki P. STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome. *Clin Exp Immunol* (2015) 181(1):29–38. doi:10.1111/cei.12614

107. Le Dantec C, Varin MM, Brooks WH, Pers JO, Youinou P, Renaudineau Y. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin-6 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. *J Rheumatol* (1993) 20(9):1544–9.

108. Neves FS, Carrasco S, Goldenstein-Schainberg C, Goncalves CR, de Mello SB. Neutrophil hyperchemotaxis in Behcet's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. *Clin Rheumatol* (2008) 29(12):1403–10. doi:10.1007/s10067-009-1261-5

109. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet's disease. *Rheumatology* (Oslo) (2008) 47(8):840–8. doi:10.1093/rheumatology/ken109

110. Ambrose N, Khan E, Ravindran D, Lightstone L, Abraham S, Botto M, et al. The exaggerated inflammatory response in Behcet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-gamma/CXCL10 IP-10 pathway. *Clin Exp Immunol* (2015) 181(3):427–33. doi:10.1111/cei.12655

111. Hughes T, Tire-Ozdemitir F, Alibab- Oner F, Coit P, Direskeneli H, Sawallaha AH. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation in cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet's disease. *Arthritis Rheumatol* (2014) 66(6):1648–58. doi:10.1002/art.38409

112. Slobodin G, Toukan Y, Rosner I, Rozenbaum M, Boulman N, Pavlotzky E, Versnel MA. Systemic increase in type I interferon activity in primary Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. *Immunol Lett* (2012) 15(5):R114. doi:10.1136/immunolit.2012-014333

113. Shah M, Edman MC, Janga SR, Shi P, Dhandhukia J, Liu S, et al. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. *J Control Release* (2013) 171(3):269–79. doi:10.1016/j.jconrel.2013.07.016

114. Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, et al. Criteria for diagnosis of Behcet's disease. International study group for Behcet's disease. *Lancet* (1990) 335(8697):1078–80.

115. Kanekura T, Gushi A, Ivata M, Fukumaru S, Sakamoto R, Kawahara K, et al. Treatment of Behcet's disease with granulocyte and monocyte adsortption apheresis. *J Am Acad Dermatol* (2004) 51(2 Suppl):S83–7. doi:10.1016/j.jaad.2003.12.023

116. Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of microarray and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. *Arthritis Rheum* (2008) 58(5):1465–74. doi:10.1002/art.23451

117. York MR, Nagai T, Mangini AJ, Lemaire R, van Sekenter JM, Layfatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in
patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. *Arthritis Rheum* (2007) 56(3):1010–20. doi:10.1002/art2386.

135. Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, Kuhwara M, Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. *Arthritis Res Ther* (2013) 15(4):R74. doi:10.1186/1425-

136. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. *J Clin Invest* (2007) 117(3):557–67. doi:10.1172/JCI31139.

137. Truchetet ME, Allanore Y, Montanari E, Chizzolini C, Brembilla NC. Prostaglandin I(2) analogues enhance already exuberant TH17 cell responses in systemic sclerosis. *Ann Rheum Dis* (2012) 71(12):2044–50. doi:10.1136/ annrheumdis-2012-201400.

138. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom B, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. *Ann Rheum Dis* (2010) 69(7):1396–402. doi:10.1136/ard.2009.121400.

139. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta) in patients with systemic sclerosis: MCP-1 and MIP-1 alpha may be involved in the development of pulmonary fibrosis. *Clin Exp Immunol* (1999) 117(1):159–65.

140. Giacomelli R, Cipriani P, Danese C, Pizzuto F, Lattanzio R, Parzanese I, et al. Peripherally blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. *J Rheumatol* (1996) 23(2):291–6.

141. Crestani B, Seta N, De Bandt M, Soler P, Rolland C, Dehoux M, et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. *Am J Respir Crit Care Med* (1994) 149(5):1260–5. doi:10.1164/ajrccm.149.5.8173768.

142. Deguchi Y. Spontaneous increase of transforming growth factor beta production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung. *Ann Rheum Dis* (1992) 51(3):362–5. doi:10.1136/ard.51.3.362.

143. Umehara H, Kumasagi S, Murakami M, Sugino-Ohta T, Tanaka K, Hashida S, et al. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. *Arthritis Rheum* (1990) 33(6):893–7. doi:10.1002/art.1780330619.

144. Westacott CI, Whicher JT, Hutton CW, Dieppe PA. Increased spontaneous production of interleukin-1 together with inhibitory activity in systemic sclerosis. *Clin Sci (Lond)* (1988) 75(6):561–7. doi:10.1042/cs0750561.

145. Andrews BS, Frio IJ, Berman MA, Sandborg CI, Mirick GR, Cesario TC. Changes in circulating monocytes in patients with progressive systemic sclerosis. *Rheumatology (Oxford)* (1987) 14(5):390–5.

146. Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A, et al. Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent monocyte chemoattractant protein-1 secretion in patients with Wegener's granulomatosis. *Arthritis Res Ther* (2005) 7(1):R93–100. doi:10.1186/ar1614.

147. Sambo P, Iannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion). *J Invest Dermatol* (1999) 112(1):78–84. doi:10.1046/j.1523-1747.1999.00476.x.

148. Allanore Y, Borderie D, Hilliquin P, Hernvann A, Levacher M, Lemarechal H, et al. Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. *Rheumatology (Oxford)* (2001) 40(10):1089–96. doi:10.1093/rheumatology/40.10.1089.

149. Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Sievert E, et al. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. *Arthritis Res Ther* (2014) 16(2):R65. doi:10.1186/1425-0505.

150. Yamaguchi Y, Kuhwara M. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. *Histol Histopathol* (2013) 28(2):175–83. doi:10.14670/HH-28.175.

151. Elisa T, Antonio P, Giuseppe P, Alessandro B, Giuseppe A, Federico C, et al. Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. *J Immunol* (2015) 2015:147616. doi:10.1155/2015/147616.
171. Johansson AC, Ohlsson S, Pettersson A, Bengtsson AA, Selga D, Hansson M, et al. Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis. *Arthritis Res Ther* (2016) 18:92. doi:10.1186/s13075-016-0994-1

172. Park J, Lee EB, Song YW. Decreased tumour necrosis factor-alpha production by monocytes of granulomatosis with polyangiitis. *Scand J Rheumatol* (2014) 43(5):403–8. doi:10.3109/03009742.2014.894568

173. Crawshaw A, Kendrick YR, McMichael AJ, Ho LP. Abnormalities in inKT cells are associated with impaired ability of monocytes to produce IL-10 and suppress T-cell proliferation in sarcoidosis. *Eur J Immunol* (2014) 44(7):2165–74. doi:10.1002/eji.201344284

174. Okamoto H, Mizuno K, Horio T. Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients. *J Dermatol* (2003) 30(7):503–9. doi:10.1111/j.1346-8138.2003.tb00442.x

175. Homolka J, Lorenz J, Zuchold HD, Muller-Quernheim J. Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis. *Clin Investig* (1992) 70(10):909–16. doi:10.1007/BF01080437

176. Wiken M, Grunewald J, Eklund A, Wahlstrom J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. *J Immunol* (2009) 29(1):78–89. doi:10.4049/jimmunol.1000178

177. Ina Y, Takada K, Sato T, Yamamoto M, Noda M, Morishita M. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible origin. *Chest* (1993) 102(4):1128–33. doi:10.1378/chest.102.4.1128

178. Thole AA, Rodrigues CA, Milward G, Negreiros, Porto LC, Carvalho L. Ultrastructural study of expression of adhesion molecules between blood monocytes and alveolar macrophages from patients with pulmonary sarcoidosis. *J Submicrosc Cytol Pathol* (2001) 33(4):349–24.

179. Sahashi K, Ina Y, Takada K, Sato T, Yamamoto M, Morishita M. Significance of interleukin 6 in patients with sarcoidosis. *Chest* (1994) 106(1):156–60. doi:10.1378/chest.106.1.156

180. Terao I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis. *Int Arch Allergy Immunol* (1993) 102(3):242–8. doi:10.1002/iai.111376

181. Tercelj M, Stopinske S, Ihan A, Salobir B, Simcic S, Bramber B, et al. In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis. *Clin Exp Immunol* (2011) 166(1):87–93. doi:10.1111/j.1365-2249.2011.04456.x

182. Barth J, Entzian P, Petermann W. Increased release of free oxygen radicals by phagocytosing and nonphagocytosing cells from patients with active pulmonary sarcoidosis as revealed by luminol-dependent chemiluminescence. *Klin Wochenschr* (1988) 66(7):292–7. doi:10.1007/BF01727514

183. Baranowska A, Tyykkä M, Wibulskaja M, Szadurska M, Nowakowski S, Stanieczuk-Panasik A, et al. Changed phagocytic activity and pattern of Fc gamma and complement receptors on blood monocytes in sarcoidosis. *Hum Immunol* (2012) 73(8):788–94. doi:10.1016/j.humimm.2012.05.005

184. Heron M, Grutters JC, van Velzen-Blad H, Veltkamp M, Claessen AME, van den Bosch JMM. Increased expression of CD16, CD69, and very late antigen-1 on blood monocytes in active sarcoidosis. *Int J Biol Sci* (2013) 9(4):432–8. doi:10.4137/BIOSCI.2013.0211

185. Mysliwska J, Smardzewski M, Marek-Trzonkowska N, Mysliwiec M, Racynska K. Expansion of CD14+CD16+ monocytes producing TNF-alpha in complication-free diabetes type 1 juvenile onset patients. *Cytokine* (2012) 60(1):309–17. doi:10.1016/j.cyto.2012.03.010

186. Larsen SA, She JX, Scharz D, Fullker K, Hutson AD, Peng RH, et al. Aberrant monocyte prostatic gland synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. *Pediatr Diabetes* (2003) 4(1):10–8. doi:10.1034/j.1399-9004.2003.00042.x

187. Mysliwska J, Smardzewski M, Marek-Trzonkowska N, Mysliwiec M, Racynska K. Expansion of CD14+CD16+ monocytes producing TNF-alpha in complication-free diabetes type 1 juvenile onset patients. *Cytokine* (2012) 60(1):309–17. doi:10.1016/j.cyto.2012.03.010

188. Harsunen MH, Puff R, D’Orlando O, Giannopoulos E, Lachmann M, Beyerlein A, et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. *Horm Metab Res* (2015) 47(6):467–70. doi:10.1055/s-0034-1331226

189. Ismail NA, Abd El Baky AN, Ragab S, Hamed M, Hashmi MA, Shehata A. Monocyte cytotoxicant enzyme chemotractor protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes. *J Pediatr Endocrinol Metab* (2016) 29(6):641–5. doi:10.1515/jpem-2015-0340

190. Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, et al. A type I interferon transcriptional signature precedes autoimmunity in childhood genetically at risk for type 1 diabetes. *Diabetes* (2014) 63(7):2538–50. doi:10.2337/db13-1777

191. Wolter TR, Wong R, Sarkar SA, Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. *Clin Immunol* (2009) 132(1):103–15. doi:10.1016/j.clim.2009.02.007

192. Alkanani AK, Reeves M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated toll-like receptor-induced interleukin-1beta and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. *Diabetes* (2012) 61(10):2525–33. doi:10.2337/db12-0099

193. Hara N, Alkanani AK, Dinarello CA, Zipris D. Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade. *Innate Immun* (2014) 20(6):574–84. doi:10.1111/j.1775-1974.2013.00242.x

194. Londono P, Komura A, Hara N, Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. *Clin Immunol* (2010) 133(3-4):401–11. doi:10.1016/j.clim.2010.01.007

195. Hara N, Alkanani AK, Dinarello CA, Zipris D. Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. *J Mol Med (Berl)* (2014) 92(1):93–102. doi:10.1007/s00109-013-1078-1

196. Gottlieb PA, Alkanani AK, Michels AW, Lewis EC, Shapiro I, Dinarello CA, et al. alpha1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1beta responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. *J Clin Endocrinol Metab* (2014) 99(8):E1418–26. doi:10.1210/jc.2013-3864

197. Litherland SA. Immunopathogenic interaction of environmental triggers and genetic susceptibility in diabetes: is epigenetics the missing link? *Diabetes* (2008) 57(12):3186–4. doi:10.2337/db08-0242

198. Chen Z, Xiao F, Peterson AD, Lachin JM, Zhang L, Schones DE, et al. Epigenetic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes
Arts et al. TRIM in Diseases

Ibrahim JN, Jounblat R, Delwail A, Abou-Ghoch J, Salem N, Chouery E, Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome Carta S, Tassi S, Delfino L, Omenetti A, Raffa S, Torrisi MR, et al. Deficient Todd I, Radford PM, Ziegler-Heitbrock L, Ghaemmaghami AM, Powell RJ, Bachetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic Vento-Tormo R, Alvarez-Errico D, Garcia-Gomez A, Hernandez-Irvine KM, Gallego P, An X, Best SE, Thomas G, Wells C, et al. Peripheral blood bone monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes. Diabetes (2012) 61(5):1281–90. doi:10.2337/ db11-1549

Rousseau MC, El-Zein M, Conus F, Legault L, Parent ME. Bacillus Calmette-Guerin (BCG) vaccination in infancy and risk of childhood diabetes. Pediatri Permut Epidemiol (2010) 36(2):141–8. doi:10.1111/j.1365-2233.2009.03481.x

Borghini S, Ferrera D, Prigione I, Fiore M, Ferrari S, Sirisola V, et al. Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation. Clin Exp Rheumatol (2016) 34(6 Suppl 102):S121–8.

Bacchetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autoimmunity and inflammation in protein aggregation diseases. J Mol Med (Berl) (2014) 92(6):583–94. doi:10.1007/s00109-014-1150-5

Todd I, Radford PM, Ziegler-Heitbrock L, Khan Maghami AM, Powell RJ, Tige P. Elevated CD16 expression by monocytes from patients with type 1 diabetes. Diabetes (2004) 53(11):4182–6. doi:10.2337/diabetes.53.11.4182

Ibrahim JN, Joublat R, Delwail A, Abou-Ghoch J, Salem N, Chouery E, et al. Ex vivo response of monocytes of familial Mediterranean fever patients: Involvement of IL-1beta, IL-1alpha and TH17-associated cytokines and decrease of TH1 and TH2 cytokines. Cytokine (2014) 69(2):248–54. doi:10.1016/j.cyto.2014.06.012

Schattner A, Lachmi M, Livneh A, Pras M, Hahn T. Tumor necrosis factor in familial Mediterranean fever. Am J Med (1991) 90(4):434–8. doi:10.1016/s0002-9343(96)70002-t

Davytn T, Hakopyan GS, Avetisyan SA, Mkrtchyan NR. Impaired endotoxin tolerance induction in patients with familial Mediterranean fever. Pathobiology (2006) 73(1):26–39. doi:10.1159/000093089

Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol (1999) 26(9):1983–6.

Simsek I, Pay S, Pekel A, Dinc A, Musabuk U, Erdem H, et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int (2007) 27(9):807–11. doi:10.1002/art.23133

Davytn T, Harutyunyan VA, Hakopyan GS, Avetisyan SA, Heightened endotoxin susceptibility of monocytes and neutrophils during familial Mediterranean fever. FEMS Immunol Med Microbiol (2008) 52(3):370–8. doi:10.1111/j.1574-695X.2008.00385.x

Drenth JP, Cuissett L, Grateau G, Vasquez C, de Veltde Viisser SD, de Jong JG, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet (1999) 22(2):178–81. doi:10.1038/9696

Houten SM, Ruis W, Duran M, de Koning T, van Royen-Kerkhof A, Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet (1999) 22(2):175–7. doi:10.1038/9691

van der Meer JW, Vossem JS, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet (1984) 1(8386):1087–90. doi:10.1016/S0140-6736(84)92504-5

Drenth JP, van der Meer JW, Kusmer J. Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J Immunol (1996) 157(1):400–4.

Stoffels M, Jongebrugge J, Remijin T, Kok N, van der Meer JW, Simon A. TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology (Oxford) (2015) 44(2):363–8. doi:10.1093/rheumatology/keu341

Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol (2015) 34(8):1333–9. doi:10.1007/s10067-015-2923-0

Mulders-Manders CM, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what's new? Semin Immunopathol (2015) 37(4):371–6. doi:10.1007/s00281-015-0492-6

Arostegui JI, Anton J, Calvo I, Robles A, Iglesias E, Lopez-Montesinos B, et al. Open-label, phase II study to assess the efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndromes. J Allergy Clin Immunol (2017) 139(1):202–11.e6. doi:10.1016/j.jaci.2016.05.016

Vento-Tormo R, Alvarez-Errico D, Garcia-Gomez A, Hernandez-Rodriguez J, Bujan S, Basagana M, et al. DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes. Am J Hum Genet (2014) 92(6):1175–9. doi:10.1016/j.ajhg.2012.10.030

van der Meer JW, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin-1 protects granulocytic mice from lethal granulocytopenic infection. Proc Natl Acad Sci U S A (1991) 88(5):1620–3. doi:10.1073/pnas.85.3.1620

van't Wout JW, van der Meer JW, Barza M, Dinarello CA. Protection of neutrophilic mice from lethal Candida albicans infection by recombinant interleukin-1. Eur J Immunol (1998) 28(7):1143–6. doi:10.1002/eji.1830180072

Liese JG, Jendrossek V, Jansson A, Petropoulou T, Kloos S, Gahr M, et al. Chronic granulomatous disease in adults. Lancet (1996) 347(8996):220–3. doi:10.1016/S0140-6736(96)90403-1

Rieber N, Hector A, Kuipers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol (2012) 2012;52460. doi:10.1155/2012/52460

van de Veerdonk FL, Smeekens SF, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A (2010) 107(7):3030–3. doi:10.1073/pnas.0917495107
246. Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. *Blood* (2010) 116(9):1570–3. doi:10.1182/blood-2010-01-264218

247. Gabrion A, Hmitou I, Moshous D, Neven B, Lefevre-Utile A, Diana JS, et al. Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease. *J Allergy Clin Immunol* (2017) 139(5):1641–9e6. doi:10.1016/j.jaci.2016.08.033

248. Selmeczy Z, Szelenyi J, Nemet K, Vizi ES. The inducibility of TNF-alpha production is different in the granulocytic and monocytic differentiated forms of wild type and CGD-mutant PLB-985 cells. *Immunol Cell Biol* (2003) 81(6):472–9. doi:10.1046/j.1440-1711.2003.01190.x

249. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. *Proc Natl Acad Sci U S A* (2014) 111(9):3526–31. doi:10.1073/pnas.1322831111

250. van de Veerdonk FL, Dinarello CA. Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. *Autophagy* (2014) 10(6):1141–2. doi:10.4161/auto.28638

251. Schappi M, Deffert C, Fiette L, Gavazzi G, Herrmann F, Belli D, et al. Branched fungal beta-glucan causes hyperinflammation and necrosis in phagocyte NADPH oxidase-deficient mice. *J Pathol* (2008) 214(4):434–44. doi:10.1002/path.2298

252. Deffert C, Carnesecchi S, Yuan H, Rougemont AL, Kelkka T, Holmdahl R, et al. Hyperinflammation of chronic granulomatous disease is abolished by NOX2 reconstitution in macrophages and dendritic cells. *J Pathol* (2012) 228(3):341–50. doi:10.1002/path.4061

253. Brown KL, Bylund J, MacDonald KL, Song-Zhao GX, Elliott MR, Falsafi R, et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. *Clin Immunol* (2008) 129(1):90–102. doi:10.1016/j.clim.2008.06.005

254. De Ravin SS, Zarember KA, Long-Priol D, Chan KC, Fox SD, Gallin JI, et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. *Blood* (2010) 116(10):1755–60. doi:10.1182/blood-2009-07-233734

255. Fujigaki H, Saito K, Fujigaki S, Takekura M, Sudo K, Ishiguro H, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. *J Biochem* (2006) 139(4):655–62. doi:10.1093/jb/mvj072

256. Bernardo J, Brennan L, Brink HF, Ortiz MF, Newburger PE, Simons ER. Chemotactic peptide-induced cytoplasmatic pH changes in incubated human monocytes. *J Leukoc Biol* (1993) 53(6):673–8. doi:10.1002/jlb.53.6.673

257. Broen JC, Bossini-Castillo L, van Bon L, Vonk MC, Knaapen H, Beretta L, et al. A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. *Arthritis Rheum* (2012) 64(1):264–71. doi:10.1002/art.33325

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.